Publications
- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine
- Acrodermatitis continua Hallopeau successfully treated by risankizumab2021 | Third Faculty of Medicine
- Coexistence of palmoplantar pustulosis and ichthyosis vulgaris treated by risankizumab2021 | Third Faculty of Medicine
- Léčba risankizumabem u dvou pacientů s těžkou psoriázou po switchi z jiné biologické terapie2021 | Third Faculty of Medicine
- 1 Nehtová psoriáza léčená risankizumabem2021 | Third Faculty of Medicine
- Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry2023 | Third Faculty of Medicine, First Faculty of Medicine
- Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer2023 | Third Faculty of Medicine
- 19 Psoriasis2023 | Third Faculty of Medicine
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Prevalence of genital and oral human papillomavirus infection among psoriasis patients on biologic therapy2022 | Third Faculty of Medicine, Second Faculty of Medicine, Faculty of Science
Loading network view...